Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of dapagliflozin on GFR changes across chronic kidney disease stages
IRCT20241204063939N1Phase 2Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dapagliflozin in chronic kidney disease (CKD), sponsored by Arak University of Medical Sciences. Primary endpoint: Change in GFR over time. Started Mar 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20241204063939N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241204063939N1.